Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI reads heart ultrasound videos to pick best candidates for valve repair

NCT ID NCT07247890

Knowledge-focused Sponsor: Beijing Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study aims to create an artificial intelligence (AI) model that analyzes ultrasound videos of the heart to help doctors decide if a patient with a leaky mitral valve (mitral regurgitation) is a good candidate for a minimally invasive repair procedure called TEER. The researchers will use data from 800 patients across multiple centers to build and test the AI. The goal is to make the preoperative assessment faster, more objective, and easier to use, especially in primary care settings.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AI model (Vision Mamba) for preoperative assessment
What this could lead to
If successful, this could provide a faster, more objective way to identify which patients with mitral regurgitation are good candidates for a minimally invasive heart valve repair, potentially improving surgical outcomes and healthcare efficiency.
What could go wrong
This is an early-stage model development study, not a treatment trial. The AI may not perform as well in real-world settings or across different patient groups, and it will need further validation before it can be used in clinical practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 800 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Dec 2025

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population was drawn from Beijing Hospital and Fuwai Hospital of the Chinese Academy of Medical Sciences.

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age: 18-90 years 2. Patients with moderate to severe or severe mitral regurgitation as indicated by echocardiography Exclusion Criteria: 1. Moderate or severe aortic stenosis or aortic regurgitation, or following aortic valve replacement 2. Patients with congenital heart disease 3. Poor image quality: Insufficient cross-sectional coverage or inability to perform effective mitral valve marking

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Mitral regurgitation (MR) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

mitral valve insufficiency

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Mitral regurgitation (MR)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.